PharmaShots | Incisive News in 3 Shots

Subscribe Now

Adjuvant Therapy

Chugai's Kadcyla (trastuzumab emtansine) Receives MHLW's Approval for Adjuvant Therapy of HER2-Positive Early Breast Cancer

Chugai's Kadcyla (trastuzumab emtansine) Receives MHLW's Approval for Adjuvant Therapy of HER2-Positive Early Breast Cancer

August 24, 2020

Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan

Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER...

September 2, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us